Evidence map›Paper›PMID 35892316›Full record

Trial reportClinical pharmacology and therapeutics2022

Organic Anion Transporter Gene Variants Associated With Plasma Exposure and Long-Term Response to Atrasentan in Patients With Diabetic Kidney Disease.

J David Smeijer, Jeroen V Koomen, Donald E Kohan, John J V McMurray, George L Bakris, Ricardo Correa-Rotter, Fan-Fan Hou, Dalane W Kitzman, Hirofumi Makino, Gert Mayer and 7 more

Open access · hybridAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Clinical pharmacology and therapeutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Review
  5. Can Pharmacogenetic Variants inInternational journal of molecular sciences · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 14 institutions in 11 countries.

J David SmeijerDepartment of Clinical Pharmacy and Pharmacology, University of Groningen, Groningen, The Netherlands.ORCID 0000-0003-1725-9927
Jeroen V KoomenDepartment of Clinical Pharmacy and Pharmacology, University of Groningen, Groningen, The Netherlands.ORCID 0000-0001-7253-3998
Donald E KohanDivision of Nephrology, University of Utah Health, Salt Lake City, Utah, USA.ORCID 0000-0002-3981-2941
John J V McMurrayBritish Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.
George L BakrisAmerican Society of Hypertension Comprehensive Hypertension Center, University of Chicago Medicine and Biological Sciences, Chicago, Illinois, USA.ORCID 0000-0003-1183-1267
Ricardo Correa-RotterNational Medical Science and Nutrition Institute Salvador Zubirán, Mexico City, Mexico.
Fan-Fan HouDivision of Nephrology, Nanfang Hospital, Southern Medical University, National Clinical Research Center for Kidney Disease, Guangzhou, China.ORCID 0000-0003-3117-7418
Dalane W KitzmanSections on Cardiovascular Disease and Geriatrics, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA.
Hirofumi MakinoOkayama University, Okayama, Japan.
Gert MayerDepartment of Internal Medicine IV (Nephrology and Hypertension), Medical University of Innsbruck, Innsbruck, Austria.
Michal NowickiDepartment of Nephrology, Hypertension and Kidney Transplantation, Medical University of Lodz, Lodz, Poland.ORCID 0000-0002-0823-5440
Vlado PerkovicGeorge Institute for Global Health, Newtown, New South Wales, Australia.
Peter RossingSteno Diabetes Center, Gentofte, Denmark.
Sheldon TobeDivision of Nephrology, Sunnybrook Health Sciences Centre, University of Toronto and the Northern Ontario School of Medicine, Toronto, Ontario, Canada.
Hans-Henrik ParvingDepartment of Medical Endocrinology, Rigshospitalet Copenhagen University Hospital, Copenhagen, Denmark.
Dick de ZeeuwDepartment of Clinical Pharmacy and Pharmacology, University of Groningen, Groningen, The Netherlands.
Hiddo J L HeerspinkDepartment of Clinical Pharmacy and Pharmacology, University of Groningen, Groningen, The Netherlands.
University of Groningen · NLBritish Heart Foundation · GBCopenhagen University Hospital · DKInnsbruck Medical University · ATInstituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán · MXMedical University of Lodz · PLNanfang Hospital · CNOkayama University · JPSunnybrook Health Science Centre · CAUniversity of Chicago · USUniversity of Copenhagen · DKUniversity of Utah · USUNSW Sydney · AUWake Forest University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Plasma exposure of the endothelin receptor antagonist atrasentan varies between individuals and is associated with nephroprotective effects and the risk of heart failure. We examined the influence of genetic polymorphisms on atrasentan plasma exposure and pharmacodynamic effects. We performed a substudy of the Study of Diabetic Nephropathy With Atrasentan (SONAR) trial which enrolled adults with type 2 diabetes and chronic kidney disease (estimated glomerular filtration rate: 25-75 mL/min/1.73 m

Indexed as

Diabetes Mellitus, Type 2Diabetic NephropathiesHeart FailureOrganic Anion TransportersAlbuminsAtrasentanCreatinineEndothelin-1Endothelin Receptor AntagonistsHumansLiver-Specific Organic Anion Transporter 1AlbuminsAtrasentanCreatinineEndothelin-1Endothelin Receptor AntagonistsLiver-Specific Organic Anion Transporter 1Organic Anion TransportersSLCO1B1 protein, human

Identifiers

PMID35892316
PMCPMC9804438
OpenAlexW4288067911

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.